(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are REDITUS,SGPS, XXL, and ITERA.

Financial Asset	Price	Change	Updated (EST)
REDITUS,SGPS (RED.LS)	0.09	14.47%	2023-10-24 12:23:40
XXL (XXL.OL)	0.79	10.49%	2023-10-24 12:44:12
ITERA (ITERA.OL)	12.60	7.69%	2023-10-24 12:40:36
HÖEGH AUTOLINERS (HAUTO.OL)	88.45	6.82%	2023-10-24 12:40:29
GREENYARD (GREEN.BR)	5.69	6.36%	2023-10-24 12:20:05
WALLENIUS WILHELMS (WAWI.OL)	88.15	6.33%	2023-10-24 12:44:04
ASETEK (ASTK.OL)	6.78	6.27%	2023-10-24 12:24:34
BENEVOLENTAI (BAI.AS)	0.98	5.98%	2023-10-24 12:00:50
ATOS (ATO.PA)	4.90	5.59%	2023-10-24 12:45:38
JINHUI SHIPP TRANS (JIN.OL)	6.07	5.38%	2023-10-24 12:40:38

The three biggest losers today are BERGENBIO, NORTHERN DRILLING, and AUREA.

Financial Asset	Price	Change	Updated (EST)
BERGENBIO (BGBIO.OL)	0.17	-11.73%	2023-10-24 12:24:53
NORTHERN DRILLING (NODL.OL)	1.12	-10.04%	2023-10-24 12:41:31
AUREA (AURE.PA)	4.60	-9.8%	2023-10-24 12:45:44
ULTIMOVACS (ULTI.OL)	103.80	-7.32%	2023-10-24 12:43:52
GENTIAN DIAGNOSTIC (GENT.OL)	39.00	-6.7%	2023-10-24 12:40:08
CELYAD ONCOLOGY (CYAD.BR)	0.65	-6.09%	2023-10-24 12:05:16
HOFSETH BIOCARE (HBC.OL)	2.70	-5.26%	2023-10-24 12:40:25
KOMPLETT (KOMPL.OL)	5.88	-5.16%	2023-10-24 12:40:50
PCI BIOTECH HOLD (PCIB.OL)	1.84	-4.77%	2023-10-24 12:42:02
MITHRA (MITRA.BR)	1.14	-4.69%	2023-10-24 12:20:40

Winners today

1. REDITUS,SGPS (RED.LS)

14.47% Price Change

Reditus, Sociedade Gestora de Participações Sociais, S.A., through its subsidiaries, provides business process outsourcing, IT outsourcing, and IT consulting services in Portugal and internationally. The company offers client services, including client, financial, human resource, doc, and facilities management, as well as other business process services; and IT infrastructure services and solutions in the areas of advisory, design, installation, and maintenance of systems and solutions, storage, network, and security. It also provides specialized outsourcing services in the areas of application development and maintenance, DBs and system administration, business intelligence and applications, telecom engineering and networks, and support and helpdesk; and information security services and solutions, as well as security managed services. In addition, the company offers enterprise content management services, solutions, and products for deployment of projects in scanning, document management, and workflow in multi-channel topologies; lean management services and solutions in practical application of diagnostic methodologies; and management and IT consulting services and solutions. Further, it is involved in the development, management, and maintenance of software applications and analytical solutions; and provision of cooperation and development services and solutions in the areas of corporate procurement, project management, and economic and social development, as well as training and personal development services. The company serves public, health, telecom, media, utilities, financial services, consumer, retail, and transportation sectors. The company was founded in 1966 and is headquartered in Lisbon, Portugal.

PSI ended the session with REDITUS,SGPS jumping 14.47% to €0.09 on Tuesday while PSI rose 0.46% to €6,055.55.

Earnings Per Share

As for profitability, REDITUS,SGPS has a trailing twelve months EPS of €0.18.

PE Ratio

REDITUS,SGPS has a trailing twelve months price to earnings ratio of 0.48. Meaning, the purchaser of the share is investing €0.48 for every euro of annual earnings.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.9%, now sitting on 23.77M for the twelve trailing months.

More news about REDITUS,SGPS.

2. XXL (XXL.OL)

10.49% Price Change

XXL ASA operates as a sports retailer. It offers sports equipment and sportswear for various sports, including running, football, golf, water sports, racket sports, and ice hockey; and fitness equipment, including treadmills and rowing machines, as well as food supplements and nutrition. The company also provides clothes for men, women, and children for baselayers, outerwear, casual wear, sportswear, and swimwear, as well as lifestyle shoes and winter shoes; outdoor and hunting products for fishing, wilderness living, and camping, such as tents, lavvos, sleeping bags, backpacks, cooking equipment as well as climbing gear; and hunting products, including firearms and ammunition, clothes, binoculars, optics, knives, and axes. In addition, it offers skis and ski accessories, such as shoes, poles, clothes, and other equipment for cross-country and downhill skiing, as well as snowboarding; high-end and everyday bikes comprising hybrid bikes, mountain bikes, city bikes, and electric bikes for children, women, and men; and bike equipment, such as helmets, shoes, spare parts, and clothes. Further, the company provides products that connect technology and sports/outdoor activities, including sport watches, action cameras, drones, GPS, earplugs and headphones, portable loudspeakers, sunglasses, pulse meters, power banks, and cycle computers. It operates stores in Norway, Sweden, and Finland, as well as e-commerce websites, such as xxl.no, xxl.se, xxl.fi, and xxl.dk. The company was founded in 2000 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with XXL jumping 10.49% to €0.79 on Tuesday while Oslo Børs Benchmark Index_GI jumped 0.81% to €1,264.85.

Earnings Per Share

As for profitability, XXL has a trailing twelve months EPS of kr-1.79.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.05%.

Sales Growth

XXL’s sales growth is negative 2.2% for the current quarter and 2.7% for the next.

Volatility

XXL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 6.27%, a positive 1.33%, and a positive 5.69%.

XXL’s highest amplitude of average volatility was 6.27% (last week), 6.46% (last month), and 5.69% (last quarter).

More news about XXL.

3. ITERA (ITERA.OL)

7.69% Price Change

Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with ITERA rising 7.69% to €12.60 on Tuesday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI rose 0.81% to €1,264.85, after two consecutive sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, ITERA has a trailing twelve months EPS of kr0.79.

PE Ratio

ITERA has a trailing twelve months price to earnings ratio of 15.95. Meaning, the purchaser of the share is investing kr15.95 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 97.07%.

Sales Growth

ITERA’s sales growth is 11.8% for the present quarter and 12.4% for the next.

More news about ITERA.

4. HÖEGH AUTOLINERS (HAUTO.OL)

6.82% Price Change

Höegh Autoliners ASA engages in the deep sea transportation of roll-on roll-off (RoRo) cargoes worldwide. The company offers transportation services for agricultural, automotive, boats, breakbulk, construction and mining equipment, machineries, power equipment, railcars and tramways, trucks, buses, equipment handling, and trailers. It also provides shortsea, terminal, and supply chain management services. Höegh Autoliners ASA was founded in 1927 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with HÖEGH AUTOLINERS jumping 6.82% to €88.45 on Tuesday while Oslo Børs Benchmark Index_GI rose 0.81% to €1,264.85.

Earnings Per Share

As for profitability, HÖEGH AUTOLINERS has a trailing twelve months EPS of kr26.66.

PE Ratio

HÖEGH AUTOLINERS has a trailing twelve months price to earnings ratio of 3.32. Meaning, the purchaser of the share is investing kr3.32 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.85%.

Volume

Today’s last reported volume for HÖEGH AUTOLINERS is 577456 which is 21.39% below its average volume of 734626.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.7%, now sitting on 1.4B for the twelve trailing months.

More news about HÖEGH AUTOLINERS.

5. GREENYARD (GREEN.BR)

6.36% Price Change

Greenyard NV supplies fresh, frozen, and prepared fruit and vegetables in Germany, the Netherlands, Belgium, the United Kingdom, France, the rest of Europe, and internationally. The company operates through Fresh and Long Fresh segments. The Fresh segment markets and supplies fresh fruit and vegetables, flowers and plants, and fresh produce. The Long Fresh segment processes freshly harvested fruits and vegetables into frozen food products; and offers freshly preserved fruit, vegetables, and other ambient food products, as well as ready-made products, such as soups, sauces, dips, and pasta dishes. The company was formerly known as Greenyard Foods NV and changed its name to Greenyard NV in September 2016. Greenyard NV was founded in 1965 and is based in Sint-Katelijne-Waver, Belgium.

BEL 20 ended the session with GREENYARD rising 6.36% to €5.69 on Tuesday while BEL 20 rose 0.46% to €3,340.47.

Earnings Per Share

As for profitability, GREENYARD has a trailing twelve months EPS of €0.16.

PE Ratio

GREENYARD has a trailing twelve months price to earnings ratio of 35.56. Meaning, the purchaser of the share is investing €35.56 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.95%.

Volume

Today’s last reported volume for GREENYARD is 10637 which is 34.44% above its average volume of 7912.

Moving Average

GREENYARD’s worth is under its 50-day moving average of €6.17 and way below its 200-day moving average of €6.47.

Volatility

GREENYARD’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.22%, a negative 0.72%, and a positive 1.08%.

GREENYARD’s highest amplitude of average volatility was 2.22% (last week), 1.10% (last month), and 1.08% (last quarter).

Yearly Top and Bottom Value

GREENYARD’s stock is valued at €5.69 at 22:40 EST, way below its 52-week high of €7.85 and higher than its 52-week low of €5.50.

More news about GREENYARD.

6. WALLENIUS WILHELMS (WAWI.OL)

6.33% Price Change

Wallenius Wilhelmsen ASA, together with its subsidiaries, transports and handle cars, tractors, trains, and windmills. It operates through three segments: Shipping Services, Logistics Services, and Government Services. The company provides liner services through a fleet of modern and versatile RoRo vessels, which carry a mix of products, such as auto, construction, mining, agriculture machinery, and breakbulk products. In addition, it offers inland transportation services, as well as operates vehicle and equipment processing centres and inland distribution networks. The company serves agriculture, automotive, aviation, boats and yachts, breakbulk, commercial vehicles, construction, machinery and machine tools, mining, oil and gas, power and energy, and rail industries. It operates approximately 125 vessels servicing 15 trade routes. The company was founded in 1861 and is based in Lysaker, Norway.

Oslo Børs Benchmark Index_GI ended the session with WALLENIUS WILHELMS jumping 6.33% to €88.15 on Tuesday while Oslo Børs Benchmark Index_GI rose 0.81% to €1,264.85.

Earnings Per Share

As for profitability, WALLENIUS WILHELMS has a trailing twelve months EPS of kr22.47.

PE Ratio

WALLENIUS WILHELMS has a trailing twelve months price to earnings ratio of 3.92. Meaning, the purchaser of the share is investing kr3.92 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.13%.

More news about WALLENIUS WILHELMS.

7. ASETEK (ASTK.OL)

6.27% Price Change

Asetek A/S, together with its subsidiaries, engages in the designing, developing, and marketing of liquid cooling solutions in Asia, Europe, and the Americas. The company operates through Liquid cooling, Data center and SimSports segments. Its products are used in personal computers, servers, and data centers to provide improved performance, acoustics, and energy efficiency. It serves original equipment manufacturers, resellers, and channel partners. The company was founded in 1997 and is headquartered in Aalborg, Denmark.

Oslo Børs Benchmark Index_GI ended the session with ASETEK rising 6.27% to €6.78 on Tuesday while Oslo Børs Benchmark Index_GI rose 0.81% to €1,264.85.

Earnings Per Share

As for profitability, ASETEK has a trailing twelve months EPS of kr-0.04.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.33%.

More news about ASETEK.

8. BENEVOLENTAI (BAI.AS)

5.98% Price Change

BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

AEX-Index ended the session with BENEVOLENTAI jumping 5.98% to €0.98 on Tuesday, following the last session’s upward trend. AEX-Index rose 0.35% to €721.73, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-0.47.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.97%.

More news about BENEVOLENTAI.

9. ATOS (ATO.PA)

5.59% Price Change

Atos SE provides digital transformation solutions and services worldwide. It offers advanced computing solutions; analytics, artificial intelligence, and automation solutions; cloud solutions; customer journey analytics and digital customer experience; decarbonization solutions; digital consulting; digital workplace solutions; edge computing and Internet of things solutions; and modern applications and platforms. The company also provides advance detection and response, data protection and governance, digital workplace security, IoT and OT security, trusted digital identities, and cybersecurity solutions; and infrastructure and foundation services. It serves financial services and insurance, healthcare and life sciences, manufacturing, public sector and defense, resources and services, telecom, media, and entertainment industries. The company was incorporated in 1982 and is headquartered in Bezons, France.

CAC 40 ended the session with ATOS rising 5.59% to €4.90 on Tuesday while CAC 40 rose 0.63% to €6,893.65.

Earnings Per Share

As for profitability, ATOS has a trailing twelve months EPS of €-10.01.

Volume

Today’s last reported volume for ATOS is 1507190 which is 20.21% below its average volume of 1889160.

More news about ATOS.

10. JINHUI SHIPP TRANS (JIN.OL)

5.38% Price Change

Jinhui Shipping and Transportation Limited, an investment holding company, engages in ship chartering and owning activities internationally. The company provides ship management and shipping agent services, as well as engages in the money lending and property investment activities. It also owns a fleet of twenty four grabs fitted supramaxes and one chartered-in-panamax. The company was founded in 1987 and is based in Hong Kong, Hong Kong. Jinhui Shipping and Transportation Limited operates as a subsidiary of Jinhui Holdings Company Limited.

Oslo Børs Benchmark Index_GI ended the session with JINHUI SHIPP TRANS jumping 5.38% to €6.07 on Tuesday while Oslo Børs Benchmark Index_GI rose 0.81% to €1,264.85.

Earnings Per Share

As for profitability, JINHUI SHIPP TRANS has a trailing twelve months EPS of kr-3.86.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.52%.

Yearly Top and Bottom Value

JINHUI SHIPP TRANS’s stock is valued at kr6.07 at 22:40 EST, way under its 52-week high of kr9.81 and way above its 52-week low of kr5.35.

Volatility

JINHUI SHIPP TRANS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.95%, a negative 0.15%, and a positive 1.73%.

JINHUI SHIPP TRANS’s highest amplitude of average volatility was 1.29% (last week), 1.21% (last month), and 1.73% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, JINHUI SHIPP TRANS’s stock is considered to be overbought (>=80).

Moving Average

JINHUI SHIPP TRANS’s worth is higher than its 50-day moving average of kr6.02 and way below its 200-day moving average of kr7.24.

More news about JINHUI SHIPP TRANS.

Losers Today

1. BERGENBIO (BGBIO.OL)

-11.73% Price Change

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Oslo Børs Benchmark Index_GI ended the session with BERGENBIO falling 11.73% to €0.17 on Tuesday while Oslo Børs Benchmark Index_GI rose 0.81% to €1,264.85.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-1.45.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -179.58%.

Volume

Today’s last reported volume for BERGENBIO is 149456000 which is 131.69% above its average volume of 64504300.

Moving Average

BERGENBIO’s worth is way above its 50-day moving average of kr0.13 and way under its 200-day moving average of kr4.18.

Earnings Before Interest, Taxes, Depreciation, and Amortization

BERGENBIO’s EBITDA is -2.91.

More news about BERGENBIO.

2. NORTHERN DRILLING (NODL.OL)

-10.04% Price Change

Northern Drilling Ltd. operates as an offshore drilling contractor to the oil and gas industry. The company primarily engages in acquiring and operating offshore drilling assets, as well as involved in drilling in ultra-deep water environments. Northern Drilling Ltd. was incorporated in 2017 and is based in Hamilton, Bermuda.

Oslo Børs Benchmark Index_GI ended the session with NORTHERN DRILLING sliding 10.04% to €1.12 on Tuesday while Oslo Børs Benchmark Index_GI jumped 0.81% to €1,264.85.

Earnings Per Share

As for profitability, NORTHERN DRILLING has a trailing twelve months EPS of kr-6.85.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.22%.

Volume

Today’s last reported volume for NORTHERN DRILLING is 839160 which is 125.93% above its average volume of 371420.

Yearly Top and Bottom Value

NORTHERN DRILLING’s stock is valued at kr1.12 at 22:40 EST, way under its 52-week high of kr34.90 and way higher than its 52-week low of kr1.01.

More news about NORTHERN DRILLING.

3. AUREA (AURE.PA)

-9.8% Price Change

Aurea SA engages in the recycling of black motor oil in France. The company is also involved in the manufacturing of remold tires from used tires and recycling rigid PVC. It recycles plastics and packaging products; refines and recycles aluminum; recycles copper and produces copper alloys; and treats and recycles zinc, lead, and cadmium. In addition, the comany engages in the treatment and decontamination of mercury waste. The company was formerly known as AUER and changed its name to Aurea SA in 1988. Aurea SA is based in Paris, France.

CAC 40 ended the session with AUREA falling 9.8% to €4.60 on Tuesday, after five consecutive sessions in a row of losses. CAC 40 jumped 0.63% to €6,893.65, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, AUREA has a trailing twelve months EPS of €0.74.

PE Ratio

AUREA has a trailing twelve months price to earnings ratio of 6.22. Meaning, the purchaser of the share is investing €6.22 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AUREA’s stock is considered to be overbought (>=80).

More news about AUREA.

4. ULTIMOVACS (ULTI.OL)

-7.32% Price Change

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with ULTIMOVACS sliding 7.32% to €103.80 on Tuesday while Oslo Børs Benchmark Index_GI rose 0.81% to €1,264.85.

Earnings Per Share

As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-5.5.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.11%.

More news about ULTIMOVACS.

5. GENTIAN DIAGNOSTIC (GENT.OL)

-6.7% Price Change

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. Gentian Diagnostics ASA was incorporated in 2001 and is headquartered in Moss, Norway.

Oslo Børs Benchmark Index_GI ended the session with GENTIAN DIAGNOSTIC falling 6.7% to €39.00 on Tuesday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI jumped 0.81% to €1,264.85, after two consecutive sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, GENTIAN DIAGNOSTIC has a trailing twelve months EPS of kr-0.89.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.53%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 10%, now sitting on 125.72M for the twelve trailing months.

Volume

Today’s last reported volume for GENTIAN DIAGNOSTIC is 1379 which is 54.36% below its average volume of 3022.

More news about GENTIAN DIAGNOSTIC.

6. CELYAD ONCOLOGY (CYAD.BR)

-6.09% Price Change

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with CELYAD ONCOLOGY falling 6.09% to €0.65 on Tuesday while BEL 20 jumped 0.46% to €3,340.47.

Earnings Per Share

As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.39.

Volatility

CELYAD ONCOLOGY’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.41%, a negative 0.15%, and a positive 6.49%.

CELYAD ONCOLOGY’s highest amplitude of average volatility was 3.50% (last week), 6.28% (last month), and 6.49% (last quarter).

Volume

Today’s last reported volume for CELYAD ONCOLOGY is 10145 which is 78.23% below its average volume of 46602.

More news about CELYAD ONCOLOGY.

7. HOFSETH BIOCARE (HBC.OL)

-5.26% Price Change

Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol, joint, eye, brain, and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome, and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was incorporated in 2009 and is headquartered in Ålesund, Norway.

Oslo Børs Benchmark Index_GI ended the session with HOFSETH BIOCARE dropping 5.26% to €2.70 on Tuesday while Oslo Børs Benchmark Index_GI jumped 0.81% to €1,264.85.

Earnings Per Share

As for profitability, HOFSETH BIOCARE has a trailing twelve months EPS of kr-0.28.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -108.36%.

Moving Average

HOFSETH BIOCARE’s value is below its 50-day moving average of kr2.96 and below its 200-day moving average of kr2.96.

More news about HOFSETH BIOCARE.

8. KOMPLETT (KOMPL.OL)

-5.16% Price Change

Komplett ASA operates as an online retailer of electronics and IT products in Norway, Sweden, and Denmark. The company operates through three segments: Business to Consumer (B2C), Business to Business (B2B), and Distribution. It offers consumer electronics and business solutions, including computer components, gaming, PCs, household electronics, and other computer-related products, as well as brown and white goods, and cloud-based IT solutions and services. It operates webshops under the Komplett brand; and retail stores under the Webhallen brand. The company's B2B operations include sales to companies and public entities/institutions under the Komplett Bedrift and Komplett Företag. It also distributes products to resellers and other entities under the Itegra brand. The company was formerly known as Norkom ASA and changed its name to Komplett ASA in December 2002. Komplett ASA was founded in 1991 and is headquartered in Sandefjord, Norway.

Oslo Børs Benchmark Index_GI ended the session with KOMPLETT falling 5.16% to €5.88 on Tuesday, after two sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI jumped 0.81% to €1,264.85, after two sequential sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, KOMPLETT has a trailing twelve months EPS of kr-1.67.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.63%.

More news about KOMPLETT.

9. PCI BIOTECH HOLD (PCIB.OL)

-4.77% Price Change

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD dropping 4.77% to €1.84 on Tuesday while Oslo Børs Benchmark Index_GI rose 0.81% to €1,264.85.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.81.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.54%.

Volatility

PCI BIOTECH HOLD’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.16%, a positive 1.56%, and a positive 5.58%.

PCI BIOTECH HOLD’s highest amplitude of average volatility was 5.99% (last week), 9.21% (last month), and 5.58% (last quarter).

Moving Average

PCI BIOTECH HOLD’s worth is way above its 50-day moving average of kr1.67 and under its 200-day moving average of kr2.02.

Earnings Before Interest, Taxes, Depreciation, and Amortization

PCI BIOTECH HOLD’s EBITDA is -4.54.

More news about PCI BIOTECH HOLD.

10. MITHRA (MITRA.BR)

-4.69% Price Change

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

BEL 20 ended the session with MITHRA sliding 4.69% to €1.14 on Tuesday, following the last session’s upward trend. BEL 20 rose 0.46% to €3,340.47, after five successive sessions in a row of losses, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, MITHRA has a trailing twelve months EPS of €-1.41.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -575.59%.

Yearly Top and Bottom Value

MITHRA’s stock is valued at €1.14 at 22:40 EST, way under its 52-week high of €6.87 and above its 52-week low of €1.08.

Moving Average

MITHRA’s value is way below its 50-day moving average of €1.85 and way below its 200-day moving average of €2.44.

Volume

Today’s last reported volume for MITHRA is 133299 which is 62.52% below its average volume of 355694.

More news about MITHRA.

Stay up to date with our winners and losers daily report